Scarica l'app Stockscreener
16.26
2.01%
0.3633
Bausch Lomb Corp Borsa (BLCO) Ultime notizie
Bausch & Lomb Corp Q1 2026 Financial Results and Risk Factors – Form 10-Q Highlights - Minichart
BofA Securities Maintains Bausch + Lomb Corp.(BLCO.US) With Sell Rating - 富途牛牛
Stifel Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $16 - 富途牛牛
A Quick Look at Today's Ratings for Bausch + Lomb Corp.(BLCO.US), With a Forecast Between $16 to $21 - 富途牛牛
From dry eye to glaucoma, 40+ Bausch + Lomb studies head to Denver - Stock Titan
BofA raises Bausch & Lomb stock price target on earnings beat - Investing.com Australia
Bausch & Lomb Corp (BLCO) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Evercore ISI cuts Bausch & Lomb stock price target on growth outlook - Investing.com
Bausch + Lomb (BLCO) Q1 2026 revenue rises to $1.24B as loss narrows - Stock Titan
Earnings call transcript: Bausch + Lomb exceeds Q1 2026 earnings expectations By Investing.com - Investing.com South Africa
Bausch + Lomb Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Bausch + Lomb (BLCO) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Bausch + Lomb (NYSE:BLCO) Posts Better-Than-Expected Sales In Q1 CY2026 - Yahoo Finance
Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook - The AI Journal
Bausch + Lomb posts Q1 2026 revenue $1.244B, raises FY26 revenue and EBITDA outlook - TradingView
Stronger Q1 2026 drives Bausch + Lomb (NYSE: BLCO) to raise full-year outlook - Stock Titan
bausch + lomb corporation Positive Earnings Pre-Announcements - RTTNews
Bausch + Lomb (BLCO) Q1 Earnings Report Preview: What To Look For - Yahoo Finance
Bausch & Lomb (NYSE: BLCO) executive reports tax-withheld 4,216-share RSU vesting - Stock Titan
RSU tax withholding adjusts Bausch & Lomb (NYSE: BLCO) holdings - Stock Titan
Icahn money manager sues his bosses and Bausch + Lomb over anti-white bias - MSN
RBC Capital Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Barclays Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Maintains Target Price $20 - 富途牛牛
BLCO.CA Stock Price, Quote & Chart | BAUSCH + LOMB CORP (TSX:BLCO) - ChartMill
Earnings Preview: BLCO to Report Financial Results Pre-market on April 29 - 富途牛牛
20 studies examine B vitamins for macular degeneration as new formula hits U.S. - Stock Titan
Is It Time To Reconsider Bausch + Lomb (BLCO) After Its 28% One-Year Rally? - Yahoo Finance
Bausch + Lomb targets net zero by 2050, trims lens plastic waste - Stock Titan
Bausch + Lomb (BLCO) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Why Bausch + Lomb (BLCO) Just Strengthened Something Beyond Earnings - Insider Monkey
Bausch + Lomb (BLCO) Q4 2025 Earnings Transcript - The Globe and Mail
Bausch + Lomb Corp stock (CA07174N1090): Why Google Discover changes matter more now - AD HOC NEWS
10 High Growth Canadian Stocks to Buy Now - Insider Monkey
Bausch + Lomb (NYSE:BLCO) Rating Increased to Buy at Wall Street Zen - MarketBeat
Bausch + Lomb Corporation - Baystreet.ca
Used contacts and lens packs add up: 725,000 pounds recycled - Stock Titan
Bausch & Lomb Legal Chief Sees Pay Dip To $3.6M In 2025 - Law360
Form 8-KCurrent report - ADVFN
Tudor Investment Corp ET AL Makes New Investment in Bausch + Lomb Corporation $BLCO - MarketBeat
Bausch + Lomb Corp. Opens with a 5.46% Gain, Outperforming S&P 500 - Markets Mojo
BLCO SEC FilingsBausch + Lomb Corporation 10-K, 10-Q, 8-K Forms - Stock Titan
[ARS] Bausch & Lomb Corp SEC Filing - Stock Titan
Bausch + Lomb (NYSE: BLCO) seeks approval to expand equity plan and elect board - Stock Titan
Bausch + Lomb Corporation Receives FDA 510(k) Clearance For Bi-Blade+ Dual-Port Vitrectomy Cutter And Adaptive Fluidics Advanced Update - marketscreener.com
Bausch + Lomb Corp stock: Eye health innovation drives undervaluation debate - AD HOC NEWS
Bausch + Lomb receives FDA clearance for surgical device - Investing.com
Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update - Business Wire
Bausch Lomb (NYSE:BLCO) Eye Health Story Gains Attention On Nyse Composite Today - Kalkine Media
Stifel Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $16.34 - 富途牛牛
Stocks in play: Bausch + Lomb Corporation - Yahoo! Finance Canada
A Look At Bausch + Lomb (NYSE:BLCO) Valuation As ASCRS Presentations Highlight Eye Health Portfolio - simplywall.st
Citi Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
Bausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in Europe - ChartMill
BLCO: Evercore ISI Group Adjusts Price Target While Maintaining Rating | BLCO Stock News - GuruFocus
Evercore Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Cuts Target Price to $17 - 富途牛牛
2.06%
0.93%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):